A weekly health led newsletter grounded in evidence-based medicine along with prospective randomized controlled trials (RCTs) by medical specialists. Our goal is to help you make sense of complex scientific information and turn it into clear, evidenced based practices you can use to make better decisions about your health and wellness.

TL;DR: THREE THINGS TO KNOW BEFORE READING

THE STORY

Most men are told their blood sugar is heading in the wrong direction and leave the appointment with two things: a lecture about diet and a plan to come back in three months. What they almost never get is a testosterone panel.

That is not a small oversight.

Somewhere between 25 and 50 percent of men with type 2 diabetes have clinically low testosterone. The number varies by study and population, but the finding is consistent enough that endocrinologists have been writing about it for over a decade. The metabolic panels ordered in primary care still do not reflect it.

Testosterone is not a libido hormone that happens to touch metabolism on the side. It is a metabolic hormone that also affects libido. That distinction matters because it changes what low testosterone means clinically, and it changes the questions worth asking at your next appointment.

Testosterone shapes how skeletal muscle pulls glucose out of the bloodstream. It influences where fat is stored. It modulates inflammatory signaling. It affects how cells respond to insulin. When it falls, none of those processes collapse overnight. They erode, in ways that show up years later as HbA1c is climbing and a doctor suggesting you simply cut carbs.

Does low testosterone increase type 2 diabetes risk? Multiple longitudinal studies say yes. Men with low testosterone at baseline are roughly twice as likely to develop type 2 diabetes over long-term follow-up. The association holds after adjusting for age, BMI, and activity in most studies. There is one complicating variable called sex hormone-binding globulin (SHBG) that most standard panels do not measure, and it may be doing as much predictive work as testosterone itself.

Between 25 and 50 percent of men with type 2 diabetes have clinically low testosterone. The range is wide because studies use different thresholds. The consistency is what matters: the finding holds across cohorts in the United States, Europe, and Asia. Low testosterone predicts diabetes. Diabetes correlates with low testosterone. The arrow runs both ways and the cycle amplifies over time.

The clinical routine has not caught up. Metabolic panels measure fasting glucose, HbA1c, lipids. Testosterone stays off the form to date.

HOW THE BIOLOGY WORKS

Visceral fat does something most people have not heard about. It converts testosterone into estrogen.

The enzyme is called aromatase. It sits inside fat cells, particularly the visceral kind packed around the organs. The more visceral fat a man carries, the higher his aromatase activity, and the more testosterone gets converted to estrogen before it can do anything useful. At the same time, that fat mass sends inflammatory signals that suppress the hypothalamus, which reduces the signal telling the pituitary to stimulate testosterone production.

End result: testosterone drops. The testis is not the problem. The fat is.

Doctors call this functional hypogonadism, or hypogonadotrophic hypogonadism. It is common in overweight men. It is often underdiagnosed. In many cases it is reversible with meaningful fat loss.

Then the loop closes. Lower testosterone means less lean muscle. Less muscle means less capacity to pull glucose out of the bloodstream. Worse glucose disposal deepens insulin resistance. Insulin resistance promotes fat storage. More fat means more aromatase. More aromatase means lower testosterone.

Years pass before the blood sugar test comes back abnormal.

The mechanistic case for testosterone as a metabolic hormone covers six documented pathways. They do not all carry equal evidentiary weight, and that distinction matters.

Sex hormone-binding globulin (SHBG) is a protein made in the liver. Its job is to carry testosterone through the bloodstream. When bound to SHBG, testosterone is inactive. Only the unbound fraction works in cells.

This matters more than most metabolic discussions acknowledge.

A 2009 study in the New England Journal of Medicine used Mendelian randomization to test causal direction across two independent cohorts. Genetic variants associated with higher SHBG correlated with 70 to 72 percent lower odds of type 2 diabetes, in both men and women. SHBG is doing something independent of testosterone itself.

The mechanism runs through the liver. Visceral fat suppresses SHBG production by reducing activity of a transcription factor called HNF4-alpha. The same metabolic state that produces excess fat also suppresses SHBG, which lowers total testosterone on a blood test. A man can have low total testosterone for two completely different reasons: the testes are not producing enough, or the liver has reduced the carrier protein. Treatment implications are different in each case.

One number does not tell you which problem you have.

WHAT THE CLINICAL TRIALS ACTUALLY SHOWED

The T4DM trial is the most cited piece of evidence in this space. It is also the most selectively quoted.

T4DM enrolled 1,007 Australian men aged 50 to 74, all with waist circumferences above 95 centimeters, impaired glucose tolerance or newly diagnosed type 2 diabetes, and testosterone at or below 14 nmol/L (roughly 403 ng/dL). Every participant was also enrolled in a structured lifestyle program. Testosterone undecanoate 1,000 mg was given by injection every three months versus placebo. Two years. Double-blind.

The testosterone group had 40 percent lower odds of type 2 diabetes diagnosis at two years, measured by oral glucose tolerance test. Also note that because testosterone increases red blood cell lifespan, it can lower HbA1c readings.

That 40 percent figure is real. It is also specifically applicable to overweight men with borderline glucose and borderline testosterone who are simultaneously in a lifestyle program.

TRAVERSE was a cardiovascular safety trial first. 5,246 men with preexisting or high-risk cardiovascular disease. All had testosterone below 300 ng/dL. Primary question: does TRT cause heart attacks? Answer: no. Cardiovascular event rates were similar between groups.

The diabetes result was secondary. In the full cohort: 7.3 percent of the testosterone group versus 8.2 percent on placebo developed new diabetes. Not statistically significant. That is what made headlines.

What the headlines left out: roughly 70 percent of TRAVERSE participants already had diabetes at baseline. They cannot develop new diabetes. When the analysis was restricted to the 607 men with prediabetes at entry, 31 percent on testosterone versus 40 percent on placebo progressed to diabetes. A 22.5 percent reduction, statistically significant at p=0.029. The initial NEJM presentation did not foreground that number. Subsequent reanalysis surfaced it.

T4DM and TRAVERSE do not contradict each other. They studied different populations for different primary purposes and both point the same direction.

WHAT TO DO WITH THIS

The T4DM result is frequently read as an argument for testosterone therapy. Read more carefully, it is equally an argument for lifestyle intervention as the mechanism. Both T4DM groups were doing a structured program. The testosterone group did better on glucose outcomes. The placebo group also improved.

Fat loss restores testosterone in functional hypogonadism. In men with obesity-driven testosterone suppression, losing 10 to 15 percent of body weight can raise testosterone by 100 ng/dL or more. TRT works alongside lifestyle in the population where it works. It does not replace a healthy lifestyle.

READER'S PULSE

KEY REFERENCES

Not medical advice. All content is for informational purposes only. Consult a board-certified physician before making any change to your health regimen.